Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 26 Dec 2019
Adding epoetin alfa (EA) to lenalidomide significantly helps achieve major erythroid response (MER) in patients with erythropoietin (Epo)-refractory, lower risk non-deletion 5q (non-del(5q)) myelodysplastic syndrome (MDS) compared with lenalidomide alone, according to the final results of the E2905* trial presented at ASH 2019.

IL-17A inhibitors superior to other immunomodulators in moderate-to-severe plaque psoriasis

07 Jul 2018
From the survey conducted, it is found that more than 80% of patients with psoriasis have experienced discrimination or humiliation across the world.

Interleukin 17A (IL-17A) inhibitors show better efficacy than ustekinumab in achieving clearance in adults with moderate-to-severe plaque psoriasis, a recent study has shown. Additionally, IL-17A inhibitors are generally more effective than etanercept, adalimumab and apremilast.

The network meta-analysis showed the following targeted immunomodulators in order of increasing relative risk (demonstrating greater likelihood) of achieving a 75-percent improvement on the Psoriasis Area and Severity Index (PASI) relative to placebo: apremilast (6.2), etanercept (9.6), adalimumab (13.0), ustekinumab (14.0), secukinumab (15.4), infliximab (16.2), brodalumab (17.3) and ixekizumab (17.9).

Infliximab, brodalumab and ixekizumab were shown to be statistically superior to apremilast, etanercept, adalimumab and ustekinumab. Furthermore, data from head-to-head studies showed similar results.

A previous network-meta-analysis showed that ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab and ustekinumab, as compared to placebo, were the best choices for achieving PASI 90 in patients with moderate-to-severe psoriasis based on moderate- to high-certainty evidence. [Cochrane Database Syst Rev 2017 Dec 22;12:CD01153

To assess the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis, the investigators conducted a systematic literature review of placebo-controlled and head-to-head randomized trials of eight targeted immunomodulators that evaluated clinical benefits or harm.

In addition, a network meta-analysis adjusted for placebo response was carried out to perform indirect comparisons between agents. A 75-percent improvement on the PASI was the primary outcome.

The present study was limited by mostly short-term evidence (covering 10–16 weeks) and by few direct comparisons, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 26 Dec 2019
Adding epoetin alfa (EA) to lenalidomide significantly helps achieve major erythroid response (MER) in patients with erythropoietin (Epo)-refractory, lower risk non-deletion 5q (non-del(5q)) myelodysplastic syndrome (MDS) compared with lenalidomide alone, according to the final results of the E2905* trial presented at ASH 2019.